Forget Cannabis: Psychedelic Stocks Could Be the Next Big Thing for the Decade

Did you miss the epic cannabis rally in 2018? Don’t bother. These psychedelic stocks could be next up to break the roof.

Pills spilling out of a prescription pot

Image source: Getty Images.

Cannabis stocks made enormous wealth for its shareholders in 2018 and 2019 after being legalized in Canada. If you missed the rally, then the psychedelic stocks could be next up for a breakout.

Psychedelic stocks in 2020

Regulatory support and encouraging research outcomes sent these stocks through the roof late last year. To name a few, Numinus Wellness (TSXV:NUMI) is a Canada-based healthcare company that’s working around psychedelic therapies. NUMI soared a notable 510% last year. Another stock, Mind Medicine, surged a massive 860% in 2020.

In late 2019, the U.S. FDA (Food and Drug Administration) showed a ray of hope for the industry. It affirmed that psychedelic Psilocybin could be a breakthrough therapy for depression and mental disorders.

Psilocybin is a hallucinogenic compound generally found in a type of fungi that’s as popular as magic mushrooms. Studies have shown that this compound is effective in treating mental disorders, anxiety, depression, and addictions.

Strong growth prospects

According to research, the psychedelic industry is expected to grow to $6.85 billion by 2027. That’s more than 16% compounded annually from its current size. The growth potential is significantly large considering the globally rising depression and mental disorder cases.

Interestingly, regulators showed their support for the use of Psilocybin recently, which further boosted the industry sentiment. In November last year, Health Canada approved the therapeutic consumption of Psilocybin for patients with severe depression.

Oregon also became the first U.S. state to allow medical use of psychedelics last year. Industry experts are hopeful for more regulatory support going forward. If that happens, the industry growth will remarkably accelerate, and psychedelic stocks could soon skyrocket.

Looking to bet on psychedelic stocks?

Like biotech stocks, psychedelics are also extremely volatile. Numinus Wellness has been no different. It is the first company to receive a licence from Health Canada to produce and harvest magic mushrooms and extract and research Psilocybin. Numinus reported $229,188 in revenues for the quarter ended November 30, 2020, indicating 70% growth year over year. It is a loss-making company at the moment.

Though growth potential might look attractive, psychedelic stocks could be highly risky. Their smaller size and underlying uncertainties could make their volatility hard for investors’ appetite.

$1.2 billion Mind Medicine is a Canadian neuro-pharma company that’s working in this domain. It has several drugs in various stages of clinical trials. It is also working on developing a therapy using Psilocybin. The efficacy results of the subsequent trials will be interesting to see.

The first psychedelic-drug companies ETF began trading in Canada last week. The Horizons Psychedelic Fund is currently trading at $9.4 and tracks the North American Psychedelic Index. Some of the top holdings include Compass Pathways, Numinus Wellness, and Mind Medicine that forms 10%, 9%, and 9% in the fund, respectively. Johnson & Johnson is also a part with a 5% weighting.

Bottom line

Psychedelic drugs are an industry that is taking birth. The regulations and research around it will pave the way for it. The COVID-19 pandemic has substantially added to mental health problems, which should act as a catalyst for the industry.

Notably, psychedelics are prominently used for therapeutic purposes, and the recreational use seems very low, as of now. So, one can expect relatively faster approvals from regulators, unlike cannabis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vineet Kulkarni has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson.

More on Stocks for Beginners

funds, money, nest egg
Stocks for Beginners

$10,000 Invested in These Stocks Could Make You a Fortune Over the Next 10 Years

Are you looking to make a fortune? Then you have to give time in the market. Here are a few…

Read more »

Happy shoppers look at a cellphone.
Stocks for Beginners

The TSX Is Down, But These 3 Stocks Are Beating the Market

These three stocks continue to not just outpace the TSX today but soar past it. Plus, they provide protection both…

Read more »

stock market
Stocks for Beginners

Safer Than Gold: 3 Ways to Protect the Downside of Your Portfolio

You can protect the downside of your portfolio by planning ahead with low-risk (potentially dividend) holdings.

Read more »

worry concern
Stocks for Beginners

Better Buy: Shopify vs. Constellation Software Stock

Shopify (TSX:SHOP) and Constellation Software (TSX:CSU) stocks are looking incredibly cheap amid the 2022 bear market.

Read more »

a person searches for information on the internet
Stocks for Beginners

5 Things to Know About Nutrien Stock in November 2022

Should you buy NTR stock?

Read more »

Money growing in soil , Business success concept.
Stocks for Beginners

Investing in the Stock Market Could Turn Your $10,000 Into $100,000: Here’s How

Do you want to earn $100,000 from stock market investing? Here are three simple rules to earn 10-fold returns on…

Read more »

Arrowings ascending on a chalkboard
Stocks for Beginners

3 Top Canadian Stocks to Buy Now Before They Rally

Are you looking for cheap Canadian stocks to buy before the next big rally? Her are three top stocks that…

Read more »

Businessman looking at a red arrow crashing through the floor
Dividend Stocks

2 Bargain TSX Stocks Trading Near Their 52-Week Lows

Buy when others are selling. It’s time to act and buy two bargain stocks trading near their 52-week lows after…

Read more »